[HTML][HTML] Single cycle of arsenic trioxide–based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic …
SD Gore, I Gojo, MA Sekeres, L Morris… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
SD Gore, I Gojo, MA Sekeres, L Morris, M Devetten, K Jamieson, RL Redner, R Arceci…
Journal of clinical oncology, 2010•ncbi.nlm.nih.govPurpose Event-free survival following all-trans-retinoic acid (ATRA)–based therapy for acute
promyelocytic leukemia (APL) averages 70% at 5 years. While arsenic trioxide (ATO) can
induce remissions in 95% of relapsed patients, few studies have addressed the integration
of ATO into the primary management of APL. This study examines the efficacy of a single
cycle of ATO-based consolidation therapy in a treatment regimen designed to decrease
exposure to other cytotoxic agents.
promyelocytic leukemia (APL) averages 70% at 5 years. While arsenic trioxide (ATO) can
induce remissions in 95% of relapsed patients, few studies have addressed the integration
of ATO into the primary management of APL. This study examines the efficacy of a single
cycle of ATO-based consolidation therapy in a treatment regimen designed to decrease
exposure to other cytotoxic agents.
Abstract
Purpose
Event-free survival following all-trans-retinoic acid (ATRA)–based therapy for acute promyelocytic leukemia (APL) averages 70% at 5 years. While arsenic trioxide (ATO) can induce remissions in 95% of relapsed patients, few studies have addressed the integration of ATO into the primary management of APL. This study examines the efficacy of a single cycle of ATO-based consolidation therapy in a treatment regimen designed to decrease exposure to other cytotoxic agents.
ncbi.nlm.nih.gov